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Abstract 
BACKGROUND: Head and neck cancers include malignancies of the scalp and neck skin, nasal cavity, 
paranasal sinuses, oral cavity, salivary glands, pharynx and larynx. The term ABO secretor refers to people who 
secrete blood group antigens in their body fluids such as saliva, sweat, tears, semen, and serum. Non-secretors 
refer to those who do not secrete their blood group antigens in their body fluids. The lack of blood type antigens in 
body discharge increases the susceptibility to certain types of diseases and infection. 
AIM: Our study aimed to investigate the relationship between the secretion of blood groups in the saliva of 
patients with head and neck cancers. 
MATERIAL AND METHODS: This case-control study was performed on 110 people (57 patients with head and 
neck cancer who were referred to Imam Khomeini Hospital, Tehran and 53 cancer-free controls). Five ml of non-
stimulated saliva were collected by the spitting method. By agglutination or lack of agglutination in the test tubes, 
we determined the patient’s secretor or non-secretor condition. 
RESULTS: In terms of secretor status, 52.7% of all samples were secretors. In the case group, 19 out of 57 
cases (33.3%) were secretors, and 38 were non-secretors (66.7%). In the control group, 39 out of 53 cases 
(73.6%) were secretors, and 14 cases were non-secretors (26.4%). There was a significant difference in the 
percentage of non-secretors between the two groups (p = 0.00). 
CONCLUSION: People with non-secretor status may be more prone to develop head and neck cancer. The 
presence of these antigens in saliva may have a protective effect. 
 
 
 
 
 
Introduction 
 
Head and neck cancers include malignancies 
of the scalp and neck skin, nasal cavity, paranasal 
sinuses, oral cavity, salivary glands, pharynx and 
larynx [1], considered the sixth most common cancer 
in the world, accounting for 10% of malignancies 
worldwide and 3% of malignancies in the United 
States [2], [3], [4], [5], [6]. 
Tobacco and alcohol are two major risk 
factors for head and neck cancers, especially 
squamous cell carcinoma and the probability 
increases with higher intake [7], [8]. Also, researches 
have shown the association of other agents, such as 
human papilloma virus and blood group antigens with 
cancer development [9], [10], [11], [12]. 
The term ABO secretor refers to people who 
secrete blood group antigens in their body fluids such 
as saliva, sweat, tears, semen, and serum, and non-
secretors refer to those who do not secrete their blood 
group antigens in their body fluids [13], [14]. The 
secretor gene (fucosyltransferase 2) is inherited in the 
autosomal dominant pattern: Se is the dominant form, 
and she is the recessive form. Therefore, Se Se or Se 
we are secretors, and se we are non-secretors [15]. 
According to studies, the lack of blood type antigens 
in body discharge is considered a limitation, as it 
increases the susceptibility to certain types of 
diseases, including peptic and duodenal ulcers, 
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periodontal disease and candidiasis [16], [17], [18], 
[19], [20], [21], [22]. 
The protective mechanism of the blood group 
antigens against a variety of infections is unclear, but 
it seems that it interferes on the bond between the 
microorganism and epithelial cells, because many 
bacteria show a reciprocal response to blood group 
antigens. Also, in non-secretors, lower IgA levels were 
reported in both serum and saliva. Hence, it is likely 
that specific immune responses at mucosal surfaces 
of non-secretors are weaker than secretors. Lower 
levels of IgG have also been observed in these 
individuals [13]. 
Studies on the relationship between secretor 
status and diseases such as pre-malignant and 
malignant oral lesions have shown different results. 
Cerovic et al., (2008) and Lamey et al., (1994) found 
no significant relationship between secretor status and 
oral cancer [23], [24]. While Rai et al., (2015) showed 
significantly more pre-malignant lesions in non-
secretors [25]. In Hallikeri et al. ’s study (2015), oral 
mucosal fibrosis, a pre-malignant lesion, was more 
common in non-secretors [26]. As Jamil et al., 
reported (2005) it was shown that lack of secretion of 
blood group antigens in saliva could be considered as 
a risk factor for oral cancer [27]. 
Our study aimed to investigate the 
relationship between the secretion of blood groups in 
the saliva of patients with head and neck cancers. 
 
 
Material and Methods 
 
This case-control study was performed on 57 
patients with head and neck cancer who were referred 
to Imam Khomeini Hospital in Tehran (Cancer 
Institute), and their diagnosis was determined by 
histopathologic examination. Also, 53 patients’ 
accompanies and hospital staffs were considered as 
the control group. Patients who were suffered from 
severe dry mouth for any reason, such as 
radiotherapy and those who were unable to give their 
saliva sample due to extensive oral surgery were 
excluded from the study. 
First, the information checklist was completed 
based on patients’ medical records, and then 5 ml of 
non-stimulated saliva were collected in a 15 ml falcon 
tube with a plastic cap between 9 am, and 12 am, 
while the patient was in sitting position, and then the 
tubes were placed in a boiling water bath for 10 
minutes to denature the salivary enzymes. After that, 
the tubes were centrifuged for 10 minutes at 1700 rpm 
and the supernatant layer was removed and 
transferred to 2 ml micro tubes, kept in a freezer at -
70°C until complete collection of the specimens. 
According to Cerovic et al. ’s study (2008), 
secretor status was detected using the Inhibition 
Agglutination Test (Wiener Test) [23]. 
For each case, four test tubes were prepared, 
and “A” or “B” anti-sera were added as presented in 
table 1. Test tubes 3 and 4 were considered as control 
groups. We shook all the tubes at room temperature. 
After one hour, the readings were ready. By 
agglutination or lack of agglutination in the tubes, we 
determined their secretor or non-secretor state. 
Table 1: Content of test tubes 
 Content 
Test tube 1 One drop of saliva + one drop of an anti-B+ suspension of RBC B type 
Test tube 2 One drop of saliva + one drop of an anti-A+ suspension of RBC A type 
Test tube 3 One drop of physiological saline +one drop of an anti-B+ suspension of RBC 
B type 
Test tube 4 One drop of physiological saline + one drop of an anti-B+ suspension of RBC 
B type 
 
In tubes 3 and 4, control tubes, agglutination 
occurred, and the results in tubes 1 and 2 were 
interpreted as follows: 
- Lack of agglutination in tube 1 showed 
neutralising anti-B with salivary antigen, which meant 
that antigen B was present in saliva. 
- Lack of agglutination in tube 2 showed 
neutralising anti-A with salivary antigen, which meant 
that antigen A was present in the saliva. 
- Agglutination in tube 1 showed the reaction 
between Anti-B and B red blood cells. As a result, 
antigen B was not present in saliva. 
- Agglutination in tube 2 showed the reaction 
between anti-A and “A” red blood cells. As a result, 
antigen A was not present in saliva. 
So, no agglutination in tube 1 and 
agglutination in tube 2 meant: B secretor; 
agglutination in tube 1 and no agglutination in tube 2 
meant: A secretor; lack of agglutination in both tubes 
1 and 2 meant: AB secretor; agglutination in both 
tubes 1 and 2 meant: non-secretor. The secretor 
status was considered as a nominal variable, and the 
difference between the patients’ group, compared to 
the healthy control group was assessed using the Chi-
square test. The significance level was considered 
less than 0.05.  
In this study, there was no interference in the 
patients’ treatment process, and the condition was 
only described. However, to ensure patients’ 
awareness and obtain their consent, the consent form 
was signed by all individuals and confirmed by the 
Ethics Committee with the code 
IR.SBMU.RIDS.REC.1396.479.  
 
Results 
In this case-control study, a total of 110 
people including 57 patients (25 female and 32 male) 
with a mean age of 58.69 ± 14.84 years with head and 
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neck cancer and 53 controls (26 women and 27 men) 
with a mean age of 49.13 ± 11.13 years participated. 
All patients in the case groupware admitted to the 
surgery department and Cancer Surgery Clinic of 
Imam Khomeini Cancer Institute.  
In terms of smoking and alcohol in the case 
group, 17 out of 57 smoked (29.8%) and 2 consumed 
alcohol (3.5%); these two people were alcoholics and 
smokers at the same time.  
There were 59 lesions in 57 patients, of which 
39 cases were squamous cell carcinoma (SCC), 10 
cases were basal cell carcinoma (BCC), 3 cases were 
sarcoid cell carcinoma, 3 cases were mucoepidermoid 
carcinoma (MEC), 2 cases were osteosarcoma, 1 was 
pleomorphic adenoma, and 1 was Acinic-cell 
carcinoma (ACC). Meanwhile, one patient had two 
lesions in the tongue and buccal area, and another in 
mandible and tongue simultaneously. The total 
number of lesions was 59 in 57 patients.  
The most frequent lesion site was tongue with 
13 cases; other sites involvement were as follow: 
mandibular bone 9 cases, buccal mucosa 8 cases, 
facial skin 8 cases, parotid 5 cases, larynx 4 cases, 
lip3 cases, maxillary bone 3 cases, nasal mucosa 3 
cases, maxillary sinus 2 cases and one case had oral 
floor involvement.  
The most common lesions were as amass 
(54.23%), and the rest (45.77%) were ulcerative. 
(Type of cancer, site, and shape are given in Table 2.)  
Table 2: Features of malignancies in head and neck cancers 
Variable Description  Number Percentage 
Cancer type Squamous cell carcinoma 39 66.1% 
Basal Cell Carcinoma 10 16.9% 
Spindle cell sarcoma 3 5.1% 
Mucoepidermoid carcinoma 3 5.1% 
Osteosarcoma 2 3.4% 
Pleomorphic adenoma 1 1.7% 
Adenoid cystic carcinoma 1 1.7% 
Total 59 100% 
Anatomic location Tongue 13 22..3% 
Mandible 9 15.3% 
Buccal mucosa 8 13.5% 
Skin 8 13.5% 
Parotid 5 8.4% 
Larynx 4 6.7% 
Lip 3 5.1% 
Maxilla 3 5.1% 
Nose 3 5.1% 
Sinus 2 3.3% 
The floor of the mouth 1 1.7% 
Total 59 100% 
Clinical manifestation 
of the Lesions 
 
Mass 32 54.23% 
Ulcer 27 45.77% 
total 59 100% 
 
In terms of lesions’ size, among the total of 59 
lesions, the smallest reported lesion was 5 mm, and 
the largest was 70 mm. The mean size was reported 
to be 21.19 ± 16.13 mm.  
Lymph node involvement was positive in 18 of 
57 patients (31.6%). In the case group, 38 of 57 
patients were new cases of cancer (66.7%), and 19 
cases were diagnosed to have recurrent cancer 
(33.3%).  
In terms of secretor status, 52.7% of all 
samples were secretors. In the case group, 19 out of 
57 cases (33.3%) were secretors, and 38 were non-
secretors (66.7%). In the control group, 39 out of 53 
cases (73.6%) were secretors, and 14 cases were 
non-secretors (26.4%) (Figure 1). 
 
Figure 1: Secretory status in case and control groups 
 
There was a significant difference in the 
percentage of non-secretors between the two groups 
(p = 0.00). In general, according to Wiener anti-
agglutination test, 19 out of 57 patients were a 
secretor, among whom 12 were “A” secretor, 6 were 
“B” secretor, and one was “AB” secretor.  
As mentioned above, the most common type 
of cancer among the case group was head and neck 
squamous cell carcinoma (HNSCC), 39 lesions (37 
patients) among 59 lesions (66.1%). Therefore, the 
secretor status in patients with this type of cancer was 
analysed separately. In this group, 32.4% of subjects 
were secretors, and 67.6% were non-secretors. The 
difference between non-secretors in HNSCC and the 
control group was statistically significant (Table 2). 
 
 
Discussion 
 
Blood group antigens can be present in 
physiological fluids such as saliva. The hypothesis 
that non-secretors are more likely to develop 
infections, malignant and pre-malignant oral diseases, 
chronic periodontitis and dental caries, led us to 
assess the secretor status of patients with head and 
neck malignancies [28], [29], [30].  
Fucosyltransferase 2 is an enzyme 
synthesizes by the secretor gene. This enzyme adds 
fucose to the sugar moiety of glycolipids and 
glycoproteins. By Fucosyltransferase 2 on precursor 
oligosaccharides chain (type A) H is formed in 
secretions. By adding fucose to H, fucosyltransferase 
3 can lead to the production of Le/b. Thus, all people 
whose phenotype consists of Le/b are secretors. 
Fucosylated oligosaccharides which exist at the cell 
surface participating in severe biological processes 
such as cell differentiation, cell movement and 
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adhesion. Saliva and other body secretions of ABH 
secretors contain considerable amounts of 
carbohydrates compared to non-secretors. This can 
lead to interference with previously mentioned 
functions [15]. 
In this study, 52.7% of the total population 
were secretors (33.3% of the case and 73.6% of the 
control group) with statistically significant difference (p 
< 0.001). This means that people without blood group 
antigens in the saliva may be at increased risk for 
head and neck malignancies. Some previous studies 
have suggested a lack of secretion of blood group 
antigens in saliva as a risk factor for the development 
of oral epithelial dysplasia and malignant tumours 
[26].  
It has been reported by Jamil et al., (2016) 
that 56% of the case group with oral cancer and 78% 
of the control group were secretors and there was a 
statistically significant relationship between secretor 
status and oral cancer (p < 0.01) [20]. The result of 
this study was consistent with the present study. 
While in studies by Cerovic et al., (2008) and Lamey 
et al., (1998), assessment of blood group antigens in 
patients with oral cancer showed no significant 
difference between the two groups in terms of 
secretor status (P > 0.05) [23], [24]. 
In Garrett’s study (1971), there was no 
difference between the patients with benign and 
malignant salivary gland tumours and the control 
group in terms of secretor status [30]. 
Rai et al., (2015) evaluated the secretor 
status of the blood group antigens in oral 
premalignant lesions (leukoplakia, oral lichen planus, 
and subcutaneous fibrosis). In the case group, 87% of 
the subjects and in the control group only 16% were 
non-secretor, and there was a significant relationship 
between secretor status and pre-malignant oral 
lesions (p = 0.00) [25]. These results are consistent 
with the present study. The results of Vidas and 
Temmer’s study (1999) showed no significant 
difference in saliva secretor status of patients with 
premalignant oral lesions (lichen planus, leukoplakia, 
etc.) (p = 0.05) meanwhile a higher intensity of these 
lesions was found in the non-secretor group (p = 0.01) 
that indicates the progression of pre-malignant oral 
lesions in this group of patients [31]. 
In Campi et al. ‘s study (2007) there was no 
significant relationship between oral lesions 
(malignant and premalignant) and secretor status (p = 
0.119) [29]. 
Regarding oral submucosal fibrosis (OSMF) 
as a pre-malignant lesion, the study by Hallikeri et al., 
(2015) divided the samples into three groups. In the 
end, the results indicated that all members of the first 
group (tobacco users, with submucosal fibrosis) were 
non-secretors, in the second group (tobacco users, 
without oral lesions) 84% were non-secretors, and in 
the third group (healthy control subjects) 15% were 
non-secretors. These results showed a statistically 
significant difference between the first and third 
groups, indicating the role of secretor status in the 
development of oral submucosal fibrosis [26]. 
In the study of Shahidi Dadars et al., (2016), 
most patients with lichen planus were non-secretors 
(74%), while in Bakhtiari et al. ’s study (2016) on 
patients with lichen planus 84% of the cases and 80% 
of the control group were secretors, and there was no 
statistically significant difference between the patient 
and control groups in terms of secretor status (32) (P 
= 0.73).  
Another study by Lamey et al., (1991) showed 
that the percentage of non-secretors in the case group 
(68%) was significantly higher than the control group 
(38%) [21]. 
Lack of blood antigens in the saliva facilitates 
the long-term bonding of Candida to the mucosa. In 
potentially malignant diseases with Candida infection 
superimposition, nitrosamines produced by Candida 
can -directly or with other carcinogenic substances- 
activate specific proto-oncogenes and induce the 
development of malignant lesions [26].  
Also, in non-secretors, lower IgA levels were 
reported in both serum and saliva. Therefore, it is 
likely that specific immune responses are weaker at 
mucosal surfaces of non-secretors, in comparison 
with secretors. Lower levels of IgG have also been 
observed in these individuals [13]. 
The study of Shahidi Dadras et al., (2016) on 
the secretor status of patients with oral lichen planus 
supported the hypothesis that the blood gene antigens 
on cell surfaces played a role in protecting mucosal 
surfaces from external pathogens [32]. 
In conclusion, the significant difference 
between secretor and non-secretor status in 
cancerous patients indicates that people with non-
secretor status may be more prone to develop head 
and neck cancer. The presence of these antigens in 
saliva may have a protective effect.  
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